SCHEMBL5569783

SCHEMBL5569783

Cc1cc(CCCc2ccc(C(=O)O)c(C(=O)O)c2)ccc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT8 Q9H7Z6 2/20 0.57
PPARA Q07869 2/20 0.54
LCK P06239 2/20 0.53
KLKB1 P03952 1/20 0.49
CTSB P07858 1/20 0.49
MMP9 P14780 1/20 0.49
DNMT1 P26358 1/20 0.49
DNMT3B Q9UBC3 1/20 0.49
DNMT3L Q9UJW3 1/20 0.49
DNMT3A Q9Y6K1 1/20 0.49
ESR1 P03372 1/20 0.49
ESR2 Q92731 1/20 0.49
EGFR P00533 1/20 0.47
HMGB1 P09429 1/20 0.46
CXCL12 P48061 1/20 0.46
MCL1 Q07820 4/20 0.46
BCL2L1 Q07817 2/20 0.46
RARB P10826 1/20 0.46
HNF4A P41235 1/20 0.44
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL254346 0.85 KAT8 (0.54) KAT8PPARALCKKLKB1CTSB
SCHEMBL5570240 0.83 KAT8 (0.60) KAT8PPARALCKKLKB1CTSB
SCHEMBL529618 0.83 ESR1 (0.68) ESR1ESR2IGF1RALOX15
SCHEMBL5565669 0.81 ESR1 (0.45) KAT8PPARAESR1ESR2IGF1R
SCHEMBL8159417 0.79 KAT8 (0.62) KAT8PPARALCKKLKB1CTSB
SCHEMBL2687820 0.79 KAT8 (0.62) KAT8PPARALCKKLKB1CTSB
SCHEMBL68664 0.79 ESR1 (0.68) KAT8ESR1ESR2IGF1RALOX15
SCHEMBL27918636 0.79 CYP1A2 (0.54) KAT8ESR1ESR2IGF1RALOX15
SCHEMBL23265352 0.79 KLKB1 (0.79) KAT8LCKKLKB1CTSBMMP9
SCHEMBL7071495 0.78 HDAC1 (0.50) KAT8PPARALCKHNF4AIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312249-B2 Vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-12-25 US disclosed
US-20050182144-A1 Novel vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182144-A1 Novel vitamin D analogues CYP24A1, CYP2R1, VDR KAT8 4452/4885PPARA 134/4885LCK 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.